Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal

Inclusion Criteria: * Between 18 and 80 years old. * With liver cirrhosis diagnosed by previous biopsy or by clinical criteria, and analytical image. * No esophageal varices (or with small varices without red signs) in a recent videogastroscophy (\<3 months before randomization). * Absence of ascites demonstrated by a recent ultrasound (\<3 months before the randomization). * informed consent Exclusion Criteria: * previous decompensation of liver cirrhosis associated with portal hypertension. * GPVH \<10 mmHg. * Portal axis thrombosis affecting the portal trunk or main hepatic branches, or the splenic or mesenteric vein. * Hepatocellular carcinoma demonstrated by two imaging tests. * Bilirubin\> 3 mg / dl (or\> 50 micromol / l), platelets \<30 x10E9/lo Quick \<30%. * Presence of renal insufficiency (serum creatinine\> 2 mg / dl or\> 200 micromol / l). * Any comorbidity involving a therapeutic limitation and / or a prognosis of life \<12 months. * Absolute contraindication to treatment with β-blockers (severe bronchospasm, stenosis aortic A-V block, intermittent claudication, severe psychosis, bronchial asthma) * Hypersensitivity to β-blockers. * Pregnancy or lactation. * To receive anticoagulant treatment. * Past treatment with nitrated or β-blockers in the two weeks prior inclusion. * Cirrhosis C virus active antiviral therapy.